Relmada Therapeutics Ownership | Who Owns Relmada Therapeutics?


OverviewForecastFinancialsChartTranscripts

Relmada Therapeutics Ownership Summary


Relmada Therapeutics is owned by 42.04% institutional investors, 10.75% insiders, and 47.21% retail investors. Ikarian capital is the largest institutional shareholder, holding 5.55% of RLMD shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.57% of its assets in Relmada Therapeutics shares.

RLMD Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockRelmada Therapeutics42.04%10.75%47.21%
SectorHealthcare Stocks 231.98%10.74%-142.72%
IndustryBiotech Stocks 381.47%10.55%-292.02%
IdeaPsychedelic Stocks List20.20%9.72%70.08%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ikarian capital1.84M5.55%$3.70M
Blackrock funding, inc. /de1.27M3.82%$6.12M
Vanguard group1.20M3.63%$5.81M
Geode capital management854.93K2.58%$4.13M
Driehaus capital management740.01K2.23%$1.49M
Boothbay fund management693.24K2.09%$1.39M
Blackrock573.31K1.90%$1.72M
Acadian asset management526.72K1.59%$2.54M
Advisorshares investments319.51K0.96%$1.54M
Marshall wace, llp272.05K0.82%$546.83K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Ikarian capital1.84M0.37%$3.70M
Advisorshares investments319.51K0.26%$1.54M
Apricus wealth47.46K0.12%$229.24K
Eam investors162.55K0.09%$785.13K
Parsons capital management inc/ri263.00K0.07%$1.27M
Pandora wealth20.00K0.06%$96.60K
Spotlight asset group20.00K0.04%$60.00K
Boothbay fund management693.24K0.02%$1.39M
Rbf capital163.26K0.01%$328.15K
Driehaus capital management740.01K0.01%$1.49M

Top Buyers

HolderShares% AssetsChange
Ikarian capital1.84M0.37%1.80M
Vanguard group1.20M0.00%784.73K
Blackrock funding, inc. /de1.27M0.00%759.50K
Boothbay fund management693.24K0.02%693.24K
Geode capital management854.93K0.00%558.72K

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---674.83K
Palo alto investors lp---495.15K
Vestal point capital, lp---490.00K
Opaleye management---480.00K
Millennium management64.36K0.00%-277.09K

New Positions

HolderShares% AssetsChangeValue
Boothbay fund management693.24K0.02%693.24K$1.39M
Eam investors162.55K0.09%162.55K$785.13K
Goldman sachs group145.00K0.00%145.00K$700.35K
Sei investments98.97K0.00%98.97K$478.00K
Jefferies financial group21.66K0.00%21.66K$104.59K

Sold Out

HolderChange
Blackston financial advisory group-2.00
Innealta capital-5.00
Smartleaf asset management-35.00
Qube research-56.00
Larson financial group-100.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202543-4.44%13,954,17380.30%427.73%2237.50%8-27.27%
Sep 30, 202544-8.33%7,739,57845.94%239.13%16-5.88%10-23.08%
Jun 30, 2025476.82%5,303,149-14.73%153.82%1741.67%12-14.29%
Mar 31, 202544-15.38%6,219,493-25.95%202.64%12-36.84%14-33.33%
Dec 31, 202420-73.68%5,351,011-56.77%171.05%6-70.00%8-68.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF851.92K2.57%-
Vanguard Total Stock Mkt Idx Inv803.29K2.42%-48.63K
Biotech Growth Ord1.52M2.07%1.52M
Franklin Biotechnology Discv A(acc)USD623.80K2.07%-221.90K
Franklin Biotechnology Discovery A336.31K1.11%-120.09K
Vanguard Institutional Extnd Mkt Idx Tr798.97K1.09%1.61K
Horizons Psychedelic Stock ETF227.04K0.75%-36.13K
Fidelity Extended Market Index389.86K0.53%248.12K
AdvisorShares Psychedelics ETF338.87K0.46%-
Bridgeway Ultra-Small Company100.18K0.33%-

Recent Insider Transactions


DateNameRoleActivityValue
Dec 15, 2025TRAVERSA SERGIO Chief Executive OfficerBuy$113.30K
Dec 15, 2025Shenouda Maged Chief Financial OfficerBuy$48.06K
Nov 05, 2025Shenouda Maged Chief Financial OfficerBuy$1.10M
Nov 05, 2025Ence Chuck CAO and COOBuy$299.20K
Nov 05, 2025TRAVERSA SERGIO Chief Executive OfficerBuy$599.50K

Insider Transactions Trends


DateBuySell
2025 Q46-
2025 Q33-
2025 Q28-
2024 Q4--
2024 Q38-

RLMD Ownership FAQ


Who Owns Relmada Therapeutics?

Relmada Therapeutics shareholders are primarily institutional investors at 42.04%, followed by 10.75% insiders and 47.21% retail investors. The average institutional ownership in Relmada Therapeutics's industry, Biotech Stocks , is 381.47%, which Relmada Therapeutics falls below.

Who owns the most shares of Relmada Therapeutics?

Relmada Therapeutics’s largest shareholders are Ikarian capital (1.84M shares, 5.55%), Blackrock funding, inc. /de (1.27M shares, 3.82%), and Vanguard group (1.2M shares, 3.63%). Together, they hold 13.00% of Relmada Therapeutics’s total shares outstanding.

Does Blackrock own Relmada Therapeutics?

Yes, BlackRock owns 1.90% of Relmada Therapeutics, totaling 573.31K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.72M$. In the last quarter, BlackRock decreased its holdings by -4.874K shares, a -0.84% change.

Who is Relmada Therapeutics’s biggest shareholder by percentage of total assets invested?

Ikarian capital is Relmada Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.37% of its assets in 1.84M Relmada Therapeutics shares, valued at 3.7M$.

Who is the top mutual fund holder of Relmada Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Relmada Therapeutics shares, with 2.57% of its total shares outstanding invested in 851.92K Relmada Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools